CTLA4 Polymorphisms and De Novo Malignancy Risk after Renal Transplantation in Chinese Recipients

Abstract EN

Genetic polymorphisms in cytotoxic T lymphocyte-associated antigen 4 (CTLA4) play an influential role in graft rejection and the long-term clinical outcome of organ transplantation.

We investigated the association of five CTLA4 single-nucleotide polymorphisms (SNPs) (rs733618 C/T, rs4553808 A/G, rs5742909 C/T, rs231775 A/G, and rs3087243 G/A) with de novo malignancy in 1463 Chinese renal transplantation (RT) recipients who underwent a 192-month follow-up.

Multivariate analyses revealed that recipient rs231775 genotype is significantly associated with tumorigenesis ( P = 0.012 ).

Multiplicative interaction between rs231775 AA and possible risk factors of malignancy revealed two significant results: rs231775 AA × primary diseases and rs231775 AA × number of HLA-mismatch.

The frequency of haplotype TACAG was significantly higher in the tumor group (17.07%) than that in the nontumor group (1.53%).

In addition, aristolochic acid nephropathy ( P = 0.003 ) and the time of discovery of tumor ( P = 0.000 ) also were independently associated with tumorigenesis.

Our data show that the CTLA4 genotype rs231775 AA may be one of risk factors for the development of malignancy and haplotype TACAG was susceptible haplotype in Chinese kidney transplant recipients.